in01 vaccine
Vaccineexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2020 (NCT04537130)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07205796 | Phase 2 | May 1, 2026 | Government of China |
| NCT06375512 | Phase 1 | Jul 5, 2024 | Government of China |
| NCT04537130 | Phase 1 | Dec 1, 2020 | Hospital El Pilar, IN3BIO, Institute of Oncology Dr. Rosell (IOR), PANGAEA |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 2 | 2 | 2024 |
| Hospital El Pilar | Academic/Hospital | 1 | 0 | 1 | 2020 |
| IN3BIO | For profit | 1 | 0 | 1 | 2020 |
| Institute of Oncology Dr. Rosell (IOR) | Academic/Hospital | 1 | 1 | 1 | 2020 |
| PANGAEA | For profit | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1